neisseria meningitidis group b factor h binding protein subfamily a

`neisseria meningitidis group b factor h binding protein subfamily a` refers to a recombinant protein vaccine candidate specifically targeting the Subfamily A (variants 2 and 3) of the factor H binding protein (fHbp) found on the surface of *Neisseria meningitidis* serogroup B. Developed and sponsored by Assistance Publique - Hôpitaux de Paris (AP-HP), this investigational vaccine was evaluated in Phase 1 clinical trials (e.g., NCT01437618) to determine its safety and immunogenicity in healthy adults. fHbp is a key virulence factor that allows the meningococcus to evade the host's alternative complement pathway by binding human factor H. By immunizing with the Subfamily A variant, the vaccine aims to elicit high titers of serum bactericidal antibodies (hSBA) that block factor H binding and promote complement-mediated lysis of the bacteria. While licensed bivalent vaccines like Trumenba incorporate both Subfamily A and B antigens, this specific candidate represents a focused approach to targeting Subfamily A strains.

Other names

neisseria meningitidis group b factor h binding protein subfamily afHbp subfamily A vaccinerecombinant factor H binding protein subfamily A